NYSE:CRL Charles River Laboratories International (CRL) Stock Price, News & Analysis $156.22 +3.79 (+2.49%) Closing price 05/20/2026 03:59 PM EasternExtended Trading$156.24 +0.02 (+0.01%) As of 05/20/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Charles River Laboratories International Stock (NYSE:CRL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CRL alerts:Sign Up Key Stats Today's Range$147.51▼$157.0450-Day Range$149.88▼$185.9052-Week Range$132.58▼$228.88Volume880,507 shsAverage Volume929,650 shsMarket Capitalization$7.53 billionP/E RatioN/ADividend YieldN/APrice Target$205.86Consensus RatingModerate Buy Company Overview Charles River Laboratories International, Inc. is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission. Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities. Over the decades the company has expanded its expertise in genetics, microbiology and laboratory animal medicine, integrating new technologies such as genomics, imaging and biomarker analysis to enhance study design and data generation. This history of innovation has positioned Charles River as a partner of choice for organizations seeking to de-risk novel compounds and streamline development timelines. Today, Charles River operates in more than 20 countries across North America, Europe and the Asia-Pacific region, with research centers, laboratories and breeding facilities designed to meet international standards of quality and compliance. The company serves a diverse customer base that includes global pharmaceutical firms, emerging biotech companies, academic institutions and government agencies. Under the leadership of Chairman and Chief Executive Officer James C. Foster, Charles River continues to invest in new platforms and geographic expansion to address evolving needs in drug discovery and development.AI Generated. May Contain Errors. Read More Charles River Laboratories International Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreCRL MarketRank™: Charles River Laboratories International scored higher than 63% of companies evaluated by MarketBeat, and ranked 328th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingCharles River Laboratories International has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 11 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialCharles River Laboratories International has a consensus price target of $205.86, representing about 31.8% upside from its current price of $156.22.Amount of Analyst CoverageCharles River Laboratories International has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Charles River Laboratories International's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth8.60% Earnings GrowthEarnings for Charles River Laboratories International are expected to grow by 8.60% in the coming year, from $11.05 to $12.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Charles River Laboratories International is -41.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Charles River Laboratories International is -41.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioCharles River Laboratories International has a PEG Ratio of 1.74. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCharles River Laboratories International has a P/B Ratio of 2.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Charles River Laboratories International's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.04% of the float of Charles River Laboratories International has been sold short.Short Interest Ratio / Days to CoverCharles River Laboratories International has a short interest ratio ("days to cover") of 4.54.Change versus previous monthShort interest in Charles River Laboratories International has recently decreased by 28.23%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCharles River Laboratories International does not currently pay a dividend.Dividend GrowthCharles River Laboratories International does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest7 people have searched for CRL on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Charles River Laboratories International insiders have not sold or bought any company stock.Percentage Held by Insiders1.30% of the stock of Charles River Laboratories International is held by insiders.Percentage Held by Institutions98.91% of the stock of Charles River Laboratories International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Charles River Laboratories International's insider trading history. Receive CRL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRL Stock News HeadlinesCharles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing SolutionsMay 13, 2026 | businesswire.comCharles River Accelerates Digital Pathology with AI-Powered End-to-End WorkflowMay 11, 2026 | finance.yahoo.comTomorrow's Stock of the DayLooking for better stock ideas? Sign-up to receive The Early Bird Stock of the Day. Each day, MarketBeat's team of expert research analysts identifies one compelling stock and provides both a bull case and a bear case for each company. | The Early Bird (Ad)Is It Time To Rethink Charles River Laboratories (CRL) After Its Recent Price Rebound?May 9, 2026 | finance.yahoo.comCharles River Laboratories International, Inc. (NYSE:CRL) Q1 2026 Earnings Call TranscriptMay 8, 2026 | insidermonkey.comCRL Q1 deep dive: Portfolio restructuring and cost initiatives set stage for margin expansionMay 8, 2026 | msn.comCharles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comCharles River Q1 Review: Near-Term Stability But Long-Term Risks (Downgrade)May 7, 2026 | seekingalpha.comSee More Headlines CRL Stock Analysis - Frequently Asked Questions How have CRL shares performed this year? Charles River Laboratories International's stock was trading at $199.62 at the start of the year. Since then, CRL shares have decreased by 21.7% and is now trading at $156.2240. How were Charles River Laboratories International's earnings last quarter? Charles River Laboratories International, Inc. (NYSE:CRL) posted its earnings results on Thursday, May, 7th. The medical research company reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.10. The firm's revenue was up 1.2% compared to the same quarter last year. Read the conference call transcript. Is Charles River Laboratories International buying back stock? Charles River Laboratories International's board authorized a share repurchase plan on Wednesday, August 7th 2024, which allows the company to buy back $1,000,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 9.6% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's board believes its shares are undervalued. Does Charles River Laboratories International have any subsidiaries? The following companies are subsidiaries of Charles River Laboratories International: Vigene Biosciences Inc., Retrogenix Limited, Cognate BioServices, HemaCare, CiToxLAB, MPI Research, KWS BioTest, and more. Who are Charles River Laboratories International's major shareholders? Charles River Laboratories International's top institutional investors include Allspring Global Investments Holdings LLC (4.04%), Dimensional Fund Advisors LP (3.35%), Bank of America Corp DE (2.36%) and Amundi (1.61%). Insiders that own company stock include James C Foster, Birgit Girshick, Joseph W Laplume, William D Barbo, Victoria L Creamer, Richard F Wallman, Michael Gunnar Knell, George Massaro and Shannon M Parisotto. View institutional ownership trends. How do I buy shares of Charles River Laboratories International? Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Charles River Laboratories International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Charles River Laboratories International investors own include NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC), Home Depot (HD) and Alphabet (GOOG). Company Calendar Last Earnings5/07/2026Today5/21/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CRL's financial health is in the Red zone, according to TradeSmith. CRL has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Medical Services Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:CRL CIK1100682 Webwww.criver.com Phone(781) 222-6000Fax978-988-5665Employees19,700Year Founded1947Price Target and Rating Average Price Target for Charles River Laboratories International$205.86 High Price Target$265.00 Low Price Target$160.00 Potential Upside/Downside+31.8%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($3.76) Trailing P/E RatioN/A Forward P/E Ratio14.14 P/E Growth1.74Net Income-$144.34 million Net Margins-4.59% Pretax Margin-4.11% Return on Equity15.36% Return on Assets6.61% Debt Debt-to-Equity Ratio0.90 Current Ratio1.36 Quick Ratio1.03 Sales & Book Value Annual Sales$4.02 billion Price / Sales1.87 Cash Flow$22.51 per share Price / Cash Flow6.94 Book Value$61.17 per share Price / Book2.55Miscellaneous Outstanding Shares48,170,000Free Float47,542,000Market Cap$7.53 billion OptionableOptionable Beta1.44 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NYSE:CRL) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Charles River Laboratories International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Charles River Laboratories International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
